Ranbaxy Laboratories comes into black for Q1CY12

09 May 2012 Evaluate

Drug maker Ranbaxy Laboratories has reported higher than expected profit for the quarter ended March 31, 2012.

The company has posted a net profit of Rs 827.23 crore for Q1CY12 as compared to net loss of Rs 52.90 crore for the Q1CY11. The company’s total income has increased by 72.26% to Rs 2050.11 crore for the quarter as compared to Rs 1190.14 crore for the similar quarter of previous fiscal.

On consolidated basis, group’s net profit after tax, minority interest and share of profit of associates zoomed by 309.59% at Rs 1246.76 crore for the January-March quarter as compared to Rs 304.39 crore for the similar quarter a period ago. Group’s total income has risen by 71.84% to Rs 3923.47 crore for the quarter under review from Rs 2283.19 crore for the quarter ended March 31, 2011. The estimates were that the group would report a growth of 34% year-on-year in its profit after tax at Rs 408 crore for the first quarter of CY12.

As of March 2012, Ranbaxy had 45% market share in the Lipitor generic market. In Q4, Lipitor generic contributed USD 300 million to revenues and market share was 42% with price erosion of 65%.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×